收费全文 | 8153篇 |
免费 | 515篇 |
国内免费 | 55篇 |
耳鼻咽喉 | 80篇 |
儿科学 | 183篇 |
妇产科学 | 312篇 |
基础医学 | 1013篇 |
口腔科学 | 161篇 |
临床医学 | 766篇 |
内科学 | 1942篇 |
皮肤病学 | 118篇 |
神经病学 | 658篇 |
特种医学 | 455篇 |
外科学 | 1138篇 |
综合类 | 55篇 |
一般理论 | 5篇 |
预防医学 | 428篇 |
眼科学 | 190篇 |
药学 | 582篇 |
中国医学 | 19篇 |
肿瘤学 | 618篇 |
2023年 | 50篇 |
2022年 | 170篇 |
2021年 | 303篇 |
2020年 | 133篇 |
2019年 | 176篇 |
2018年 | 230篇 |
2017年 | 194篇 |
2016年 | 192篇 |
2015年 | 212篇 |
2014年 | 274篇 |
2013年 | 401篇 |
2012年 | 568篇 |
2011年 | 562篇 |
2010年 | 354篇 |
2009年 | 297篇 |
2008年 | 448篇 |
2007年 | 463篇 |
2006年 | 443篇 |
2005年 | 436篇 |
2004年 | 393篇 |
2003年 | 332篇 |
2002年 | 281篇 |
2001年 | 132篇 |
2000年 | 110篇 |
1999年 | 100篇 |
1998年 | 106篇 |
1997年 | 97篇 |
1996年 | 95篇 |
1995年 | 90篇 |
1994年 | 93篇 |
1993年 | 70篇 |
1992年 | 82篇 |
1991年 | 54篇 |
1990年 | 54篇 |
1989年 | 67篇 |
1988年 | 67篇 |
1987年 | 48篇 |
1986年 | 44篇 |
1985年 | 49篇 |
1984年 | 40篇 |
1983年 | 28篇 |
1982年 | 29篇 |
1981年 | 24篇 |
1980年 | 22篇 |
1979年 | 20篇 |
1978年 | 20篇 |
1977年 | 17篇 |
1976年 | 25篇 |
1971年 | 17篇 |
1969年 | 17篇 |
Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献
Visible light spectroscopy (VLS) represents a sensitive, non-invasive method to quantify tissue oxygen levels and detect hypoxemia. The aim of this study was to assess the microperfusion patterns of the gastric pouch during laparoscopic Roux-en-Y gastric bypass (LRYGB) using the VLS technique.
MethodsTwenty patients were enrolled. Tissue oxygenation (StO2%) measurements were performed at three different localizations of the gastric wall, prior and after the creation of the gastric pouch, and after the creation of the gastro-jejunostomy.
ResultsPrior to the creation of the gastric pouch, the lowest StO2% levels were observed at the level of the distal esophagus with a median StO2% of 43 (IQR 40.8–49.5). After the creation of the gastric pouch and after the creation of the gastro-jejunostomy, the lowest StO2% levels were recorded at the level of the His angle with median values of 29% (IQR 20–38.5) and 34.5% (IQR 19–39), respectively. The highest mean StO2 reduction was recorded at the level of the His angle after the creation of the gastric pouch, and it was 18.3% (SD ± 18.1%, p < 0.001). A reduction of StO2% was recorded at all localizations after the formation of the gastro-jejunostomy compared to the beginning of the operation, but the mean differences of the StO2% levels were statistically significant only at the resection line of the pouch and at the His angle (p = 0.044 and p < 0.001, respectively).
ConclusionGastric pouch demonstrates reduction of StO2% during LRYGB. VLS is a useful technique to assess microperfusion patterns of the stomach during LRYGB.
Graphical abstract